AAPG

Ascentage Pharma Group International American Depository Shares

AAPG

Market cap $3.65B

Overview Fund Activity

39.21 USD

+0.58

1.5%

At close Updated Sep 16, 4:00 PM EDT

1 day

1.5%

5 days

-1.97%

1 month

-17.44%

3 months

22.04%

6 months

99.24%

Year to date

125.6%

1 year

125.6%

5 years

125.6%

10 years

125.6%

About: Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Employees: 567

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

100% more funds holding

Funds holding: 6 [Q1] → 12 (+6) [Q2]

0.03% more ownership

Funds ownership: 0.07% [Q1] → 0.09% (+0.03%) [Q2]

38% less capital invested

Capital invested by funds: $5.21M [Q1] → $3.22M (-$1.99M) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

See Fund Rankings

Financial journalist opinion

Based on 4 articles about AAPG published over the past 30 days

Ascentage Pharma Group International (AAPG) Presents At Citi's Biopharma Back To School Conference Transcript

Ascentage Pharma Group International (NASDAQ:AAPG ) Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants Veet Misra - Chief Financial Officer Conference Call Participants John Whittaker Presentation John Whittaker Okay. Nice to see everyone here in the room today.

Ascentage Pharma Group International (AAPG) Presents At Citi's Biopharma Back To School Conference Transcript

Zacks Investment Research

Ascentage Pharma Group International - Unsponsored ADR (AAPG) Upgraded to Buy: What Does It Mean for the Stock?

Ascentage Pharma Group International - Unsponsored ADR (AAPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ascentage Pharma Group International - Unsponsored ADR (AAPG) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research

Here's Why Ascentage Pharma Group International - Unsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for Ascentage Pharma Group International - Unsponsored ADR (AAPG), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Ascentage Pharma Group International - Unsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

ROCKVILLE, Md. and SUZHOU, China, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred hereinto as “Ascentage Pharma,” the “Company,” “we,” “us” or “our”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today reported its unaudited financial results for the six months ended June 30, 2025, and provided updates on key ongoing clinical programs and commercial activities.

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025

ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that it will release its six months 2025 unaudited interim results and provide business updates at 7:00 pm Eastern Daylight Time (EDT) on August 20, 2025 / 7:00 am Hong Kong Time (HKT) on August 21, 2025.

Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025

Ascentage Pharma to Participate in Evercore China Biotech Summit

ROCKVILLE, Md. and SUZHOU, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that the Company's management will participate in the Evercore China Biotech Summit being held on August 19 - 21, 2025 in Shanghai, China.

Ascentage Pharma to Participate in Evercore China Biotech Summit

Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement

ROCKVILLE, Md. and SUZHOU, China, July 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced the closing of an offshore placement (the “Offshore Placement”), pursuant to which Dajun Yang Dynasty Trust, an affiliate of the Company's Chief Executive Officer, Dajun Yang, M.D., Ph.D. (the “Vendor”), offered and sold 22 million ordinary shares, par value US$0.0001 per share, of the Company (the “Placement Shares”) at a price of HKD68.60 per share. In connection with the Offshore Placement, the Vendor has subscribed for, and the Company will issue to the Vendor, 22 million new ordinary shares of the Company (the “Replacement Shares”) at a price of HKD68.60, resulting in net proceeds to the Company of approximately HKD1,492 million (approximately US$190.1 million based on an exchange rate of 1 USD to 7.85 HKD). The issuance of the Replacement Shares is expected to take place by July 28, 2025. The newly issued equity capital in the Company will represent approximately 6.29% of the Company's issued share capital prior to the closing of the Offshore Placement. These transactions were conducted in accordance with the terms of the Placing and Subscription Agreement by and among the Company, the Vendor and J.P. Morgan (Asia Pacific) Limited and Citigroup Global Markets Limited, each in the role of a placing agent, dated July 14, 2025.

Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement

Ascentage Pharma Announces Pricing of Top-Up Placement

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced the pricing of 22 million ordinary shares, par value $0.0001 per share, of the Company (the “Placement Shares”), at a price of HKD68.60 per share, in the offering by Dajun Yang Dynasty Trust, an affiliate of the Company's Chief Executive Officer, Dajun Yang, M.D., Ph.D. (the “Vendor”) in an offshore transaction outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”)(the “Offshore Placement”), for aggregate gross proceeds of approximately HKD1,509.2 million (or approximately US$192.3 million based on exchange rate of 1 USD to 7.85 HKD), before deducting placing fees and other offering expenses. The Offshore Placement, which was oversubscribed by eight times, is expected to close on July 17, 2025.

Ascentage Pharma Announces Pricing of Top-Up Placement

Ascentage Pharma Announces Proposed Top-Up Placement

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that Dajun Yang Dynasty Trust, an affiliate of the Company's Chief Executive Officer, Dajun Yang, M.D., Ph.D. (the “Vendor”), proposes to offer ordinary shares, par value US$0.0001 per share, of the Company (the “Placement Shares”) in an offshore transaction outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors (the “Offshore Placement”). At the time of the closing of the Offshore Placement, the Vendor would subscribe for, and the Company would issue to the Vendor new ordinary shares of the Company (the “Replacement Shares”) at the same number as the number of the Placement Shares offered in the Offshore Placement and at the same price per share as the price per share for the Placement Shares. The closing of the transaction involving the issuance of the Replacement Shares will be subject to customary closing conditions and take place after the closing of the Offshore Placement. In connection with the Offshore Placement, the representatives in the Company's U.S. initial public offering in January 2025 waived a lock-up restriction with respect to the Placement Shares held by the Vendor.

Ascentage Pharma Announces Proposed Top-Up Placement

See News Rankings

Charts implemented using Lightweight Charts™